NorthCrest Asset Manangement’s Neurocrine Biosciences NBIX Stock Holding History

NorthCrest Asset Manangement’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Sell	8,177 -1,171	-13%	-$174K	0.04%	290
2026 Q1	$1.23M	Sell	9,348 -3,647	-28%	-$484K	0.04%	294
2025 Q4	$1.77M	Buy	12,995 +2,453	+23%	+$355K	0.04%	275
2025 Q3	$1.44M	Buy	10,542 +4,280	+68%	+$580K	0.03%	281
2025 Q2	$808K	Buy	6,262 +469	+8%	+$53.8K	0.02%	339
2025 Q1	$641K	Sell	5,793 -850	-13%	-$108K	0.02%	381
2024 Q4	$907K	Buy	6,643 +1,493	+29%	+$185K	0.03%	309
2024 Q3	$593K	Buy	5,150 +10	+0.2%	+$1.37K	0.02%	378
2024 Q2	$708K	Buy	5,140 +19	+0.4%	+$2.61K	0.02%	321
2024 Q1	$706K	Sell	5,121 -270	-5%	-$36.9K	0.02%	322
2023 Q4	$710K	Hold	5,391	–	–	0.03%	315
2023 Q3	$606K	Hold	5,391	–	–	0.02%	330
2023 Q2	$508K	Hold	5,391	–	–	0.02%	352
2023 Q1	$546K	Buy	5,391 +41	+0.8%	+$4.27K	0.02%	348
2022 Q4	$639K	Hold	5,350	–	–	0.04%	241
2022 Q3	$568K	Hold	5,350	–	–	0.03%	283
2022 Q2	$522K	Hold	5,350	–	–	0.03%	300
2022 Q1	$502K	Buy	+5,350	New	+$453K	0.02%	300

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

NorthCrest Asset Manangement's NBIX Position: Q2 2026 in Review

NorthCrest Asset Manangement reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2026, selling an estimated $174K and leaving 8,177 shares worth $1.48M. The position accounts for 0.04% of the portfolio, ranked #290.

NorthCrest Asset Manangement first reported a position in NBIX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.77M in Q4 2025. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

NorthCrest Asset Manangement held 8,177 shares of Neurocrine Biosciences worth $1.48M as of Q2 2026.
NorthCrest Asset Manangement sold 1,171 Neurocrine Biosciences shares in Q2 2026, an estimated $174K.
Neurocrine Biosciences made up 0.04% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #290 holding.
NorthCrest Asset Manangement first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 18 quarters since.
NorthCrest Asset Manangement's Neurocrine Biosciences position peaked at $1.77M in Q4 2025.
388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.